Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical (Nasdaq: MBOT) announced that CEO Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit during SAGES NBT Innovation Weekend, Feb 19-21, 2026, in Houston.
The session Endovascular Therapeutics: AI and Robotics will showcase the LIBERTY Endovascular Robotic System, its single-use remote operation, and planned full market release at SIR in April 2026.
Microbot Medical (NASDAQ: MBOT) highlighted its LIBERTY Endovascular Robotic System at the International Symposium on Endovascular Therapy (ISET), Feb 9-12, 2026, where experts discussed single-use robotic solutions.
The company noted LIBERTY's FDA clearance, limited market release begun in late 2025, cross-specialty hospital use, and plans for a full market release at SIR in April 2026.
Microbot Medical (NASDAQ: MBOT) will showcase the LIBERTY Endovascular Robotic System at the Society of Interventional Oncology meeting in Savannah, Feb 4-8, 2026. The company is in a limited market release started late 2025 and will give hands-on demos to accelerate adoption ahead of a planned full release in April 2026.
LIBERTY is FDA cleared as a single-use, remotely operated robotic system for peripheral endovascular procedures, designed to improve navigation and reduce radiation exposure and operator strain.
Microbot Medical (NASDAQ: MBOT) reported 2025 progress and set 2026 targets for its LIBERTY® Endovascular Robotic System. Key 2025 milestones include FDA 510(k) clearance, a Limited Market Release with Emory University Hospital as the first adopter, ACCESS PVI pivotal-trial data showing 100% robotic navigation success and a 92% reduction in radiation, plus 20 patents granted and 52 applications pending. The company plans a Full Market Release in Q2 2026 (aligned with SIR), aims to commercialize against a 2.5 million annual US procedure opportunity, expand global reach, and grow teleintervention and IP monetization efforts.
Microbot Medical (Nasdaq: MBOT) announced Emory University Hospital as the first hospital to adopt the LIBERTY Endovascular Robotic System for patient care, and a collaboration to establish an Endovascular Robotics Program in interventional radiology.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The company commenced a limited market release and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical (NASDAQ: MBOT) announced on Nov 5, 2025 that its LIBERTY® Endovascular Robotic System is now commercially available in the U.S. via a Limited Market Release focused on selected high‑procedure‑volume regions. The system is described as the first FDA‑cleared single‑use, remotely operated robotic system for peripheral endovascular procedures; the company received FDA 510(k) clearance in September. The LMR will collect real‑world feedback to guide responsible growth, supported by a newly hired core commercial team and a third‑party logistics partner. A Full Market Release is expected at the Society of Interventional Radiology meeting in April 2026.
Microbot Medical (NASDAQ: MBOT) will commercially debut the LIBERTY® Endovascular Robotic System at the Symposium on Clinical Interventional Oncology in Miami (Oct 17-19), marking the company’s first U.S. medical meeting presence after receiving FDA 510(k) clearance in early September 2025.
The company completed hiring its commercial leadership team and secured a logistics partner while planning a limited market release in Q4 2025. Attendees can schedule live hands-on demos at booth #208.
Microbot Medical (Nasdaq: MBOT) announced a U.S.-based third-party logistics partnership to support commercialization of the FDA-cleared LIBERTY Endovascular Robotic System.
The company expects a limited market release in Q4 2025 and a broader commercial launch in April 2026 during the Society of Interventional Radiology conference. The 3PL partner offers integrated fulfillment, proximity to key markets, effective order processing, inventory maintenance, and a strategically located climate-controlled warehouse to meet expected demand.
Microbot Medical (Nasdaq: MBOT) completed the third and final closing of exercises of outstanding preferred investment options, issuing a total of 13,989,115 shares of common stock and raising approximately $29.2 million in gross proceeds across three closings ($25.2M, $1.2M, $2.8M) prior to fees.
The company issued new unregistered short-term Series J preferred investment options to purchase up to the same 13,989,115 shares with an $4.50 exercise price, exercisable beginning six months after issuance for a two-year term, representing potential additional gross proceeds of approximately $63 million if fully exercised. H.C. Wainwright acted as placement agent. Net proceeds are intended for LIBERTY robotic system development, regulatory and commercialization activities, potential acquisitions, IP applications, and working capital.
Microbot Medical (NASDAQ:MBOT) has secured its first patent in Japan for its LIBERTY® Endovascular Robotic System, strengthening its global intellectual property portfolio. The patent covers core technology including a compact robotic device for driving and manipulating elongate surgical tools.
The company has recently obtained patents in the U.S., China, and Israel over the past 90 days. Following FDA clearance on September 8, 2025, Microbot Medical is accelerating commercial launch plans, targeting an estimated 2.5 million annual peripheral endovascular procedures in the U.S. market.